UNSPSC 51281677: Tobramycin sulfate

This classification denotes an aminoglycoside antibiotic with the molecular formula 2C18H37N5O9.5H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HJT0RXD7JK, chemically known as tobramycin, free base but more generally known as tobramycin sulfate, which bears US NIH Compound Identifier 5496. European Medicines Agency schedules Tobramycin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04896MIG.

Most nations, for tariff and trade purposes, schedule tobramycin sulfate under HS 29419000 and SITC 54139. Tobramycin sulfate bears US NLM identifiers UMLS ID C0701392 and NCI Concept Code C893. SMILES: As of Q4 2014, TOBRAMYCIN SULFATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51281677 Tobramycin sulfate, a Commodity code, carries a significant mismatch between its nominal scope and recent state and local procurement activity. The code nominally identifies a specific antibiotic pharmaceutical product, yet the recent opportunities posted under it span pharmaceuticals, medical supplies, and healthcare procurement far more broadly—including naloxone and drug deactivation systems, fire-rescue medical supplies, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs. State and local issuers appear to be tagging diverse healthcare purchasing initiatives with this code despite tobramycin sulfate itself appearing in none of the recent solicitations. The actual work being bought includes emergency medical supplies procurement by fire departments and county health systems, pharmaceutical sourcing through cooperative purchasing alliances, and exploratory market research into direct manufacturer contracting models for state pharmacy benefit programs. Issuing bodies span county health departments (Seminole County, Florida), municipal fire departments (City of Tampa), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance administering contracts for member state and local facilities across multiple jurisdictions).

Geographic activity centers on Florida, Texas, and Minnesota based on recent solicitations, with Minnesota's MMCAP also serving participating jurisdictions in Oregon. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, though posting date of June 30, 2026 creates a data inconsistency), the City of Tampa's IFB for 169 line items of medical and first-aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000.00 and a Small Local Business Enterprise set-aside with a 5 percent bid discount (due March 13, 2026), the Texas Health and Human Services Commission's RFI on Direct-to-Manufacturer Prescriptions (due April 3, 2026), and Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products spanning state and local member facilities (due March 26, 2026). The code shows substantial recent activity but exhibits misalignment with its nominal pharmaceutical identity, suggesting procurement offices may be using it as a catchall for healthcare-related purchases rather than narrowly for tobramycin sulfate itself.